Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Jun 2001
Randomized Controlled Trial Clinical TrialPharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
S-mephenytoin 4'-hydroxylase (CYP2C19) catalyses the metabolism of rabeprazole to some extent. Based on the metabolic and pharmacokinetic differences among other proton pump inhibitors such as omeprazole, lansoprazole and pantoprazole, rabeprazole appears to be the least affected proton pump inhibitor by the CYP2C19-related genetic polymorphism. ⋯ The pharmacodynamic effects of rabeprazole and its pharmacokinetics depend on the CYP2C19 genotype status.